RobertODillmanMD

Chief Medical Officer of AiVita Biomedical. Previously, Dr. Dillman served as Vice President of Oncology at Caladrius Biosciences, Inc.

Join to view full profile

Dr. Dillman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Dillman's full profile

Already have an account?

Office
18301 Von Karman Ave
Ste 130
Irvine, CA 92612
Phone+1 949-735-2418
Is this information wrong?

Education & Training

University of California (San Diego) Medical CenterFellowship, Hematology and Medical Oncology, 1978 - 1980
Baylor College of MedicineResidency, Internal Medicine, 1974 - 1978
Baylor College of MedicineClass of 1973

Certifications & Licensure

CA State Medical License 1978 - 2026
TX State Medical License 1974 - 2004
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com

Clinical Trials

Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer Start of enrollment: 1992 Aug 01
Completed
Phase 2
Tumor Cell Vaccine in Treating Patients With Advanced Cancer Start of enrollment: 1992 Aug 01
Completed
Phase 2
Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer Start of enrollment: 1992 Aug 01
Completed
Phase 2
Biological Therapy in Treating Patients With Metastatic Cancer Start of enrollment: 1996 Jan 01
Completed
Phase 2
High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma Start of enrollment: 1996 Jan 01
Completed
Phase 2
Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's Lymphoma Start of enrollment: 1998 May 01
Withdrawn
Phase 2
Rituximab and Dexamethasone in Treating Patients With Recurrent or Refractory Indolent Non-Hodgkin's Lymphoma Start of enrollment: 1998 Jun 01
Withdrawn
Phase 2
Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma Start of enrollment: 1998 Jun 01
Withdrawn
Phase 2
Monoclonal Antibody Therapy or Biological Therapy in Treating Patients With Chronic Lymphocytic Leukemia or Multiple Myeloma in Remission After Chemotherapy Start of enrollment: 1998 Jun 01
Withdrawn
Phase 2
Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma Start of enrollment: 2000 Jul 01
Completed
Phase 1, Phase 2
Vaccine Therapy in Treating Patients With Kidney Cancer Start of enrollment: 2001 Nov 01
Terminated
Phase 1
Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma Start of enrollment: 2002 Jun 01
Completed
Phase 2
Cellular Adoptive Immunotherapy in Treating Patients With Glioblastoma Multiforme Start of enrollment: 1999 Feb 01
Completed
Phase 2
Vaccine Therapy and GM-CSF in Treating Patients With Recurrent or Metastatic Melanoma Start of enrollment: 2006 Dec 01
Completed
Phase 2
Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed by Surgery Start of enrollment: 2008 Nov 01
Withdrawn
Phase 2
Vaccine Biotherapy of Cancer: Autologous Tumor Cells and Dendritic Cells Start of enrollment: 2000 Oct 01
Completed
Phase 2
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma Start of enrollment: 2014 Oct 01
Terminated
Phase 3
Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas Start of enrollment: 2017 Nov 18
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

15 citations
Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment.
Daniela A Bota, Thomas H Taylor, David E Piccioni, Christopher M Duma, Renato V LaRocca, Santosh Kesari, Jose A Carrillo, Mehrdad Abedi, Robert D Aiken, Frank P K Hsu,...> ;Journal of Experimental & Clinical Cancer Research. 2022 Dec 14
4 citations
A personal COVID-19 dendritic cell vaccine made at point-of-care: Feasibility, safety, and antigen-specific cellular immune responses.
Gabriel I Nistor, Robert O Dillman, Rockelle M Robles, James L Langford, Aleksandra J Poole, Muchlis A U Sofro, Yetty M Nency, Jonny Jonny, Martina L Yana, Mahammad Ka...> ;Human Vaccines & Immunotherapeutics. 2022 Nov 30
10 citations
An update on GM-CSF and its potential role in melanoma management.
Robert O Dillman> ;Melanoma Management. 2020 Jul 29
13 citations
Cytokine network analysis of immune responses before and after autologous dendritic cell and tumor cell vaccine immunotherapies in a randomized trial
Gabriel Nistor, Robert O. Dillman> ;Journal of Translational Medicine. 2020 Apr 21
2 citations
Genomic, proteomic, and immunologic associations with a durable complete remission of measurable metastatic melanoma induced by a patient-specific dendritic cell vaccine.
Robert O. Dillman, Gabriel Nistor, Aleksandra J. Poole> ;Human Vaccines & Immunotherapeutics. 2020 Apr 2
51 citations
Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19.
Paolo A. Ascierto, Bernard A. Fox, Walter J. Urba, Ana C. Anderson, Michael B. Atkins, Ernest C. Borden, Julie R. Brahmer, Lisa H. Butterfield, Alessandra Cesano, Dani...> ;Journal for Immunotherapy of Cancer. 2020 Apr 1
Survival Comparison between Melanoma Patients Treated with Patient-Specific Dendritic Cell Vaccines and Other Immunotherapies Based on Extent of Disease at the Time of...
Robert O Dillman, Candace Hsieh> ;Biomedicines. 2019 Oct 11
4 citations
Preliminary observations on soluble programmed cell death protein-1 as a prognostic and predictive biomarker in patients with metastatic melanoma treated with patient-...
Robert O. Dillman, Gabriel Nistor, Bryce T McLelland, Candace Hsieh, Aleksandra J. Poole, Andrew N. Cornforth, Hans S. Keirstead> ;Oncotarget. 2019 Sep 3
6 citations
Patient-specific dendritic cell vaccines with autologous tumor antigens in 72 patients with metastatic melanoma
Robert O Dillman, Andrew N. Cornforth, Edward F. McClay, Carol DePriest> ;Melanoma Management. 2019 May 31
38 citations
Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses
Robert O. Dillman, Andrew N. Cornforth, Gabriel Nistor, Edward F. McClay, Thomas Amatruda, Carol DePriest> ;Journal for Immunotherapy of Cancer. 2018 Mar 6
7 citations
An update on the relevance of vaccine research for the treatment of metastatic melanoma.
Robert O. Dillman> ;Melanoma Management. 2017 Nov 23
25 citations
Is there a role for therapeutic cancer vaccines in the age of checkpoint inhibitors
Robert O Dillman> ;Human Vaccines & Immunotherapeutics. 2017 Mar 4
21 citations
Upfront boost Gamma Knife "leading-edge" radiosurgery to FLAIR MRI-defined tumor migration pathways in 174 patients with glioblastoma multiforme: a 15-year assessment ...
Christopher Duma, Brian S. Kim, Peter Chen, Marianne Plunkett, Ralph Mackintosh, Marlon S. Mathews, Ryan M Casserly, Gustavo Mendez, Daniel J Furman, Garrett Smith, Na...> ;Journal of Neurosurgery. 2016 Dec 1
1 citations
Melanoma vaccines and viral-based immunotherapies: a special focus issue from Melanoma Management .
Robert O. Dillman, Sebastian Dennis-Beron> ;Melanoma Management. 2016 Nov 30
17 citations
Dendritic cell vaccines for melanoma: past, present and future
Robert O. Dillman, Gabriel Nistor, Andrew N. Cornforth> ;Melanoma Management. 2016 Nov 29
1 citations
Long-Term Progression-Free and Overall Survival in Two Melanoma Patients Treated with Patient-Specific Therapeutic Vaccine Eltrapuldencel-T After Resection of a Solita...
Robert O. Dillman> ;Cancer Biotherapy & Radiopharmaceuticals. 2016 Apr 19
18 citations
Dendritic Versus Tumor Cell Presentation of Autologous Tumor Antigens for Active Specific Immunotherapy in Metastatic Melanoma: Impact on Long-Term Survival by Extent ...
Robert O. Dillman, Edward F. McClay, Neil M. Barth, Thomas Amatruda, Lee S. Schwartzberg, Khosrow Mahdavi, Cristina de Leon, Robin E. Ellis, Carol DePriest> ;Cancer Biotherapy & Radiopharmaceuticals. 2015 Jun 1
24 citations
Phase I trial of active specific immunotherapy with autologous dendritic cells pulsed with autologous irradiated tumor stem cells in hepatitis B-positive patients with...
Xiaojin Wang, Michael Bayer, Xiaosong Chen, Craig Fredrickson, Andrew N. Cornforth, Greg Liang, Jessica Cannon, Jia He, Qingchun Fu, Jia Liu, Gabriel Nistor, Wei Cao, ...> ;Journal of Surgical Oncology. 2015 Jun 1
6 citations
Cancer vaccines: can they improve survival?
Robert O. Dillman> ;Cancer Biotherapy & Radiopharmaceuticals. 2015 May 6
18 citations
Steadily improving survival in lung cancer.
Robert O. Dillman, Stephanie E. McClure> ;Clinical Lung Cancer. 2014 Sep 1
13 citations
High-dose IL2 in metastatic melanoma: better survival in patients immunized with antigens from autologous tumor cell lines.
Robert O. Dillman, Carol DePriest, Stephanie E. McClure> ;Cancer Biotherapy & Radiopharmaceuticals. 2014 Feb 12
23 citations
Cancer stem cell antigen-based vaccines: the preferred strategy for active specific immunotherapy of metastatic melanoma?
Robert O. Dillman, Andrew N. Cornforth, Gabriel Nistor> ;Expert Opinion on Biological Therapy. 2013 Apr 8
56 citations
Tumor stem cell antigens as consolidative active specific immunotherapy: a randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic ...
Robert O. Dillman, Andrew N. Cornforth, Carol DePriest, Edward F. McClay, Thomas Amatruda, Cristina de Leon, Robin E. Ellis, Cheryl Mayorga, Denysha Carbonell, James M...> ;Journal of Immunotherapy. 2012 Oct 1
16 citations
Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic melanoma?
Robert O. Dillman, Neil M. Barth, Louis A. VanderMolen, Khosrow Mahdavi, Stephanie E. McClure> ;Cancer Biotherapy & Radiopharmaceuticals. 2012 Jul 17
2 citations
A retrospective study of induction chemotherapy with docetaxel, cisplatinum, and 5-fluorouracil followed by concurrent radiotherapy with cetuximab in locally advanced ...
Brian S. Kim, Robert O. Dillman, Peter Chen, Russell Hafer, Craig Cox, Neil M. Barth, R. Matthew Carroll, Louis A. VanderMolen, Minh Nguyen, JinChu Huang, Annamarie Mi...> ;American Journal of Otolaryngology. 2012 Jan 1
Join now to see all

Lectures

Survival by stage and tumor measurability in metastatic melanoma patients treated with autologous dendritic cell tumor cell vaccines.
ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019

Press Mentions

AIVITA Biomedical Chief Medical Officer Dr. Robert O. Dillman to Deliver Keynote and Chair Cancer Immunotherapy Track at World Vaccine and Immunotherapy CongressNovember 29th, 2022
AIVITA Biomedical CMO Dr. Robert Dillman to Deliver Keynote at Vaccines Summit 2022October 12th, 2022
AIVITA Biomedical Announces Publication of Phase 1 and Phase 2 Trial Results of Its COVID-19 Vaccine CandidateAugust 29th, 2022
Join now to see all